ENTA · Enanta Pharmaceuticals, Inc.

Summary

At its Annual Meeting on March 11, 2026, Enanta Pharmaceuticals, Inc. stockholders re-elected Bruce L.A. Carter, Ph.D. and Jay R. Luly, Ph.D. as Class I directors, approved an amendment to the 2019 Equity Incentive Plan increasing shares reserved by 1,600,000, approved executive compensation on an advisory basis, and ratified PricewaterhouseCoopers LLP as independent auditors for fiscal 2026. The amended plan is filed as Exhibit 10.1.

Key takeaways

• Stockholders re-elected Bruce L.A. Carter, Ph.D. (20,289,217 For, 4,634,123 Withheld) and Jay R. Luly, Ph.D. (24,728,854 For, 194,486 Withheld) as Class I directors
• Approved amendment to 2019 Equity Incentive Plan adding 1,600,000 shares (19,528,223 For, 5,390,888 Against)
• Approved say-on-pay for named executive officers (24,228,898 For, 692,079 Against)
• Ratified PricewaterhouseCoopers LLP as auditors for fiscal year ending September 30, 2026 (26,825,173 For, 26,904 Against)
• Annual Meeting held March 11, 2026; amended plan filed as Exhibit 10.1